Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study

British Journal of Dermatology

Volumn 174, Issue 6, 2016, Pages 1277-1281

  Reich, K ^a   Graff, O ^b   Mehta, N ^b  

^a SCIderm Clinical Research and Dermatologikum   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CORTICOSTEROID; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAND ECZEMA; HEADACHE; HUMAN; LABORATORY TEST; LOSS OF APPETITE; MALE; MIDDLE AGED; MULTICENTER STUDY; NAIL PSORIASIS SEVERITY INDEX; PALMOPLANTAR PUSTULOSIS AREA AND SEVERITY INDEX; PHASE 2 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CARE; SKIN DISEASE ASSESSMENT; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; VITAL SIGN;

EID: 84975132506     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14401     Document Type: Article

References (17)

1. Asumalahti K, Ameen M, Suomela S et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003; 120:627–32.
2. de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat 2011; 22:102–5.
3. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009; 60:1024–31.
4. Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164:942–6.
5. Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 2009; 23:814–9.
6. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001; 40:541–2.
7. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119:755–9.
8. Lawrence CM, Marks J, Parker S, Shuster S. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984; 110:221–6.
9. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197–206.
10. Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162:952–63.
11. Bissonnette R, Diepgen TL, Elsner P et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol 2010; 24(Suppl. 3):1–20.
12. Heyman RA, Mangelsdorf DJ, Dyck JA et al. 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68:397–406.
13. Levin AA, Sturzenbecker LJ, Kazmer S et al. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 1992; 355:359–61.
14. EMC. Toctino 10 mg and 30 mg soft capsules. Available at: https://www.medicines.org.uk/emc/medicine/21177 (last accessed 14 January 2016).
15. Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012; 167:1170–4.
16. Meyer V, Goerge T, Luger TA, Beissert S. Successful treatment of palmoplantar hyperkeratotic psoriasis with a combination of etanercept and alitretinoin. J Clin Aesthet Dermatol 2011; 4:45–6.
17. Ruzicka T, Lynde CW, Jemec GB et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158:808–17.